H.C. Wainwright analyst Arthur He placed an $11 price target on Buy-rated Satellos (MSLE) Bioscience, saying the company has a “catalyst-rich” 2026 with the TRAILHEAD and BASECAMP readouts.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MSLE:
- Satellos Bioscience Posts 2025 Results, Advances SAT-3247 Into Global Phase 2 Duchenne Trials
- Cantor starts Satellos with an Overweight on DMD therapy potential
- Satellos initiated with an Overweight at Cantor Fitzgerald
- Satellos Bioscience Inc. Common Stock trading resumes
- Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause